San Diego-primarily based Viking Therapeutics marked itself as a serious competitor within the weight loss drug market place in February right after revealing promising data from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as in Ma